{"title":"备受期待的美国食品和药物管理局（FDA）关于治疗创伤后应激障碍的迷幻剂的决定最终以拒绝而告终","authors":"Valerie A. Canady","doi":"10.1002/mhw.34150","DOIUrl":null,"url":null,"abstract":"<p>In a closely watched decision involving the use of psychedelic treatment and therapy to treat post-traumatic stress disorder (PTSD), the U.S. Food and Drug Administration (FDA) on Aug. 9 declined to approve the use of midomafetamine (MDMA)-assisted therapy for the disorder. The federal agency issued a Complete Response Letter (CRL) for MDMA-assisted therapy to its drug maker, Lykos Therapeutics.</p>","PeriodicalId":100916,"journal":{"name":"Mental Health Weekly","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Much anticipated FDA decision about psychedelics for PTSD ends with denial\",\"authors\":\"Valerie A. Canady\",\"doi\":\"10.1002/mhw.34150\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>In a closely watched decision involving the use of psychedelic treatment and therapy to treat post-traumatic stress disorder (PTSD), the U.S. Food and Drug Administration (FDA) on Aug. 9 declined to approve the use of midomafetamine (MDMA)-assisted therapy for the disorder. The federal agency issued a Complete Response Letter (CRL) for MDMA-assisted therapy to its drug maker, Lykos Therapeutics.</p>\",\"PeriodicalId\":100916,\"journal\":{\"name\":\"Mental Health Weekly\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-08-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Mental Health Weekly\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/mhw.34150\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mental Health Weekly","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/mhw.34150","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Much anticipated FDA decision about psychedelics for PTSD ends with denial
In a closely watched decision involving the use of psychedelic treatment and therapy to treat post-traumatic stress disorder (PTSD), the U.S. Food and Drug Administration (FDA) on Aug. 9 declined to approve the use of midomafetamine (MDMA)-assisted therapy for the disorder. The federal agency issued a Complete Response Letter (CRL) for MDMA-assisted therapy to its drug maker, Lykos Therapeutics.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
